Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Li, Zhiping, M.D.
- Target Recruit Count
- 130
- Registration Number
- NCT01688024
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-23
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Brown University
- Target Recruit Count
- 11
- Registration Number
- NCT01671488
- Locations
- 🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States
🇺🇸Montefiore Medical Center, New York, New York, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0
- Conditions
- Interventions
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT01621217
- Locations
- 🇸🇪
Accademic Hospital, Dept. of Oncology, Uppsala, Sweden
🇳🇴University Hospital, Dept. of Oncology, Oslo, Norway
🇸🇪Skåne University Hospital, Dept. of Oncology, Lund, Sweden
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 136
- Registration Number
- NCT01580410
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Mitomycin-c Application for PRK
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01504282
- Locations
- 🇮🇷
Ophthalmic Research Center, Tehran, Iran, Islamic Republic of
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Albert Koong
- Registration Number
- NCT01327521
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT01324141
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2016-03-22
- Target Recruit Count
- 18
- Registration Number
- NCT01296763
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2014-01-31
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 39
- Registration Number
- NCT01263834
- Locations
- 🇹🇭
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University, Hat-yai, Songkhla, Thailand
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01171482
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.